KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

20 Mar 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Esophageal Squamous Cell Carcinoma (ESCC) · Phase 2 · Enrollment 60 · Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 20 Mar 2026. The item focuses on KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer. Open the detail page to review the full original feed content.